CCNE2 and breast cancer: Previous studies have demonstrated that PARI overexpression was correlated with aggressive tumor cell proliferation and poor prognosis in breast cancer [24], high expression of CCNE2 in breast cancer is strongly predictive of shorter distant metastasis-free survival following endocrine therapy [25] and RAD54B potentiates tumor growth and predicts poor prognosis of breast cancer patients [26].